Cara Therapeutics Inc. (CARA) 10.96 $CARA
Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa Opioid Receptor Agonist CR845 and Analogs for the Treatment and Prevention of Pain-Related Conditions
GlobeNewswire - Tue Feb 10, 8:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the issuance of U.S. Patent No. 8,951,970 with claims covering the use of its lead clinical compound, CR845, and related compounds of this chemical class for the treatment and prevention of a broad range of pain-related conditions.
CARA: 10.96 (-0.03)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 6:03AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 8:30 a.m. ET in New York City.
CARA: 10.96 (-0.03)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 78.09 (+1.70), DE: 90.04 (+0.67), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Cara Therapeutics Inc. (CARA) in Focus: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:18AM CST
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares rise over 6% on the day.
CARA: 10.96 (-0.03), AFFX: 11.45 (+0.02)
Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 7:10AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will become effective at market open on Monday, December 22, 2014.
CARA: 10.96 (-0.03), IBB: 323.46 (+3.04)
Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
GlobeNewswire - Wed Dec 17, 7:09AM CST
-- I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis
CARA: 10.96 (-0.03)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial
PR Newswire - Tue Dec 09, 7:10AM CST
Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful completion of the Phase 1a / 1b clinical trial of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. Cara's tablet formulation of CR845 utilizes Enteris' proprietary oral delivery technology.
CARA: 10.96 (-0.03)
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:46AM CST
Cara Therapeutics (CARA) was a big mover last session, with shares rising just over 6% on the day.
BIIB: 391.66 (-0.45), CARA: 10.96 (-0.03), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
New Medical Chief at Cara
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 9:29AM CST
CARA: 10.96 (-0.03)
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
GlobeNewswire - Tue Dec 02, 7:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Officer, effective immediately. Dr. Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
CARA: 10.96 (-0.03)
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Tue Dec 02, 7:00AM CST
-- All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
CARA: 10.96 (-0.03)
Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa Opioid Receptor Agonist CR845 and Analogs for the Treatment and Prevention of Pain-Related Conditions
GlobeNewswire - Tue Feb 10, 8:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the issuance of U.S. Patent No. 8,951,970 with claims covering the use of its lead clinical compound, CR845, and related compounds of this chemical class for the treatment and prevention of a broad range of pain-related conditions.
CARA: 10.96 (-0.03)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 6:03AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 8:30 a.m. ET in New York City.
CARA: 10.96 (-0.03)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 78.09 (+1.70), DE: 90.04 (+0.67), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Cara Therapeutics Inc. (CARA) in Focus: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:18AM CST
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares rise over 6% on the day.
CARA: 10.96 (-0.03), AFFX: 11.45 (+0.02)
Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 7:10AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will become effective at market open on Monday, December 22, 2014.
CARA: 10.96 (-0.03), IBB: 323.46 (+3.04)
Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
GlobeNewswire - Wed Dec 17, 7:09AM CST
-- I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis
CARA: 10.96 (-0.03)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial
PR Newswire - Tue Dec 09, 7:10AM CST
Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful completion of the Phase 1a / 1b clinical trial of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. Cara's tablet formulation of CR845 utilizes Enteris' proprietary oral delivery technology.
CARA: 10.96 (-0.03)
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:46AM CST
Cara Therapeutics (CARA) was a big mover last session, with shares rising just over 6% on the day.
BIIB: 391.66 (-0.45), CARA: 10.96 (-0.03), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
New Medical Chief at Cara
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 9:29AM CST
CARA: 10.96 (-0.03)
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
GlobeNewswire - Tue Dec 02, 7:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Officer, effective immediately. Dr. Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
CARA: 10.96 (-0.03)
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Tue Dec 02, 7:00AM CST
-- All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
CARA: 10.96 (-0.03)
